• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [17762 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: Efficacy and safety of immunoglobulins in rheumatology. Systematic review report]
2021     Austrian Institute for Health Technology Assessment (AIHTA) Robotics and functional electrical stimulation for stroke rehabilitation: systematic review
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Parent-Child-Pass Update 2020/21 – Screenings for mental health, nutrition and social competence]
2021     Center for Evidence-based Practice (CEP) Ambulatory blood glucose checks
2021     NIHR Public Health Research (PHR) programme A randomised controlled trial and economic evaluation of a community-based physical activity intervention to prevent mobility-related disability for retired older people. The REACT (REtirement in ACTion) study
2021     Center for Evidence-based Practice (CEP) Prevention of opioid-induced respiratory depression (OIRD) in hospital care
2021     NIHR Health Technology Assessment programme PRODIGY: Prevention and treatment of long term social disability amongst young people with emerging severe mental illness: A randomised controlled trial
2021     Center for Evidence-based Practice (CEP) Fall prevention in ambulatory care facilities
2021     Center for Evidence-based Practice (CEP) Triaging COVID-19 in the emergency department
2021     Center for Evidence-based Practice (CEP) Critical value thresholds
2021     NIHR Health Services and Delivery Research programme The TRECA study: TRials Engagement in Children and Adolescents
2021     NIHR Health Technology Assessment programme Estimating the benefits and harms of Z-drugs for people with dementia and sleep disorders
2021     NIHR Health Technology Assessment programme ROCkeTS - Refining Ovarian Cancer Test Accuracy Scores
2021     NIHR Health Technology Assessment programme A randomised pragmatic trial comparing the clinical and cost effectiveness of lithium and quetiapine augmentation in treatment resistant depression.
2021     NIHR Health Technology Assessment programme A multi-centre cluster randomised controlled trial to evaluate the Guide to Action Care Home fall prevention programme in care homes for older people (FinCH)
2021     NIHR Health Technology Assessment programme Investigating the effectiveness and cost effectiveness of using FITNET to treat paediatric CFS/ME in the UK
2021     Norwegian Institute of Public Health (NIPH) Minimally invasive glaucoma surgery (MIGS) for individuals with glaucoma. A health technology assessment
2021     NIHR Health Technology Assessment programme Statin Web-based Investigation of Side Effects Trial (Statin WISE Trial)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: Initiating diagnostic measures in a person with signs and symptoms suggestive of a urinary tract infection (cystitis or pyelonephritis) and initiating first-line pharmacological treatment for cystitis in an adult with functional autonomy decline]
2021     NIHR Health Technology Assessment programme Prognostic indicators of severe disEAse in women with late preterm pre-eClampsia tO guide deCision-maKing on timing of delivery (PEACOCK study)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: Urinary catheter placement in an adult with functional autonomy decline presenting with symptoms suggestive of acute urinary retention]
2021     NIHR Health Technology Assessment programme A randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of laparoscopic cholecystectomy compared with observation/conservative management for preventing recurrent symptoms and complications in adults with uncomplicated symptomatic gallstones (C-Gall)
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: Initiating blood work for the purpose of evaluating diagnosed or suspected alcohol use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: Initiating pharmacotherapy for relapse prevention in a person with alcohol use disorder]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [State of knowledge: Efficacy and safety of pharmacological treatments for alcohol withdrawal and relapse prevention]
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: Administration of benzodiazepines or gabapentin prescribed via an individual prescription for alcohol withdrawal]
2021     NIHR Health Services and Delivery Research programme Clinical and cost effectiveness of progressive exercise compared to best practice advice, with or without corticosteroid injection, for the treatment of rotator cuff disorders: a 2x2 factorial randomised controlled trial (The GRASP trial)
2021     NIHR Health Technology Assessment programme ALternative To prophylactic Antibiotics for the treatment of Recurrent urinary tract infections in women (ALTAR study)
2021     NIHR Public Health Research (PHR) programme The VIP trial: a randomised controlled trial of the clinical and cost effectiveness of a Victim Improvement Package (VIP) for the reduction of chronic symptoms of depression or anxiety in older victims of common crime
2021     NIHR Health Technology Assessment programme A multi-centre randomised controlled trial to compare the clinical and cost effectiveness of Lee Silverman Voice Treatment versus standard NHS speech and language therapy versus control in Parkinson's disease (PD COMM)
2021     NIHR Public Health Research (PHR) programme Does slip resistant footwear reduce slips among healthcare workers? A randomised controlled trial
2021     NIHR Health Technology Assessment programme How do smoking cessation medicines compare with respect to their neuropsychiatric safety: a systematic review, network meta-analysis and cost effectiveness analysis.
2021     NIHR Health Technology Assessment programme OPTIMA: Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis
2021     NIHR Public Health Research (PHR) programme The impact of a family-based physical activity promotion programme on child physical activity: feasibility and pilot of the Families Reporting Every Step to Health (FRESH) intervention.
2021     NIHR Health Services and Delivery Research programme Accounting for multimorbidity, competing risk and direct treatment disutility in risk prediction tools and model-based cost-effectiveness analysis for the primary prevention of cardiovascular disease and osteoporotic fracture
2021     NIHR Public Health Research (PHR) programme RISKIT-CJS Pragmatic randomized controlled trial to evaluate the effectiveness and cost-effectiveness of a multi-component intervention to reduce substance use and risk-behaviour in adolescents engaged with the criminal justice system
2021     NIHR Public Health Research (PHR) programme Evaluating graduated progress towards and impacts of the implementation of indoor smoke free prison facilities in Scotland
2021     NIHR Health Technology Assessment programme Improving the Wellbeing of people with Opioid Treated CHronic pain; I-WOTCH
2021     NIHR Health Technology Assessment programme A Phase II randomised clinical trial of conditioning cyclophosphamide and chemoembolisation with or without vaccination with dendritic cells pulsed with HepG2 lysate ex vivo in patients with Hepatocellular Carcinoma: IMMUNOTACE
2021     NIHR Health Technology Assessment programme The cystic fibrosis (CF) anti-staphylococcal antibiotic prophylaxis trial (CF START); a randomised registry trial to assess the safety and efficacy of flucloxacillin as a longterm prophylaxis agent for infants with CF
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Guidelines and standards: assessment and risk management of severe neurological complications following mild traumatic brain injury]
2021     Ontario Health Blue light (fluorescence) cystoscopy with hexaminolevulinate hydrochloride in non-muscle bladder cancer
2021     Ontario Health Internet-delivered cognitive behavioral therapy for post-traumatic stress disorder and acute stress disorder
2021     European Network for Health Technology Assessment (EUnetHTA) Comparative effectiveness of surgical techniques and devices for the treatment of benign prostatic hyperplasia
2021     Ontario Health iStent for people with open angle glaucoma
2021     Medical Services Advisory Committee (MSAC) Six genetic tests for the diagnosis of inheritable cardiac conduction disorders
2021     Ontario Health DPYD genotyping in patients with cancer treated with fluoropyrimidines
2021     Ontario Health Multi-gene pharmacogenomic testing to guide medication selection for people with major depression
2021     European Network for Health Technology Assessment (EUnetHTA) Convalescent plasma therapy for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Tocilizumab for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Camostat for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Nafamostat for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Solnatide for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Anakinra for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) APN01 for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Darunavir for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Favipiravir for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Sarilumab for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Interferon (IFN) and Novaferon (NOVA) for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Gimsilumab for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Canakinumab for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Casirivimab and imdevimab (REGN-COV2) for the treatment of COVID-19
2021     NIHR Public Health Research (PHR) programme A cluster randomised controlled trial of an intervention to improve the mental health support and training available to secondary school teachers the WISE (Wellbeing in Secondary Education) project
2021     European Network for Health Technology Assessment (EUnetHTA) Bamlanivimab for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Baricitinib for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) Molnupiravir for the treatment of COVID-19
2021     European Network for Health Technology Assessment (EUnetHTA) High-dose vitamin D for the treatment of COVID-19
2021     Center for Drug Evaluation (CDE) [Health economic evaluation of three listed anti-cancer medications]
2021     European Network for Health Technology Assessment (EUnetHTA) Mavrilimumab for the treatment of COVID-19
2021     Center for Drug Evaluation (CDE) [Review of international guidelines and comparative effectiveness of high cost antidiabetes drugs]
2021     European Network for Health Technology Assessment (EUnetHTA) Ivermectin for the treatment of COVID-19
2021     Center for Drug Evaluation (CDE) [Descriptive study and comparative effectiveness of listed medications for osteoporosis on new osteoporotic fracture event in osteoporosis patients by using National Health Insurance claim database]
2021     European Network for Health Technology Assessment (EUnetHTA) Aspirin for the treatment of COVID-19
2021     Center for Drug Evaluation (CDE) [A systematic review of the comparative efficacy and cost-effectiveness of current listed statins in Taiwan]
2021     NIHR Health Technology Assessment programme The ACUTE (Ambulance CPAP: Use, Treatment effect and Economics) feasibility study: a pilot randomised controlled trial of prehospital CPAP for acute respiratory failure
2021     Swiss Federal Office of Public Health (FOPH) Corneal collagen crosslinking for the treatment of progressive keratoconus
2021     Swiss Federal Office of Public Health (FOPH) Infliximab reference product versus biosimilar for the treatment of rheumatoid arthritis
2021     Swiss Federal Office of Public Health (FOPH) Medical cannabis for treating various symptoms in Switzerland
2021     Ontario Health Molecular testing for thyroid nodules with atypical cells of indeterminate significance
2021     Swiss Federal Office of Public Health (FOPH) Palbociclib (Ibrance®) as a treatment for advanced breast cancer
2021     NIHR Health Technology Assessment programme A non-inferiority randomised controlled trial comparing the clinical and cost-effectiveness of one session treatment (OST) with multi-session cognitive behavioural therapy (CBT) in children with specific phobias
2021     Ontario Health Nonthermal minimally invasive treatments for varicose veins
2021     Swiss Federal Office of Public Health (FOPH) Surgical intervention in shoulder impingement syndrome
2021     Ontario Health Prostatic artery embolization for benign prostatic hyperplasia
2021     Swiss Federal Office of Public Health (FOPH) The treatment of primary hypercholesterolaemia and mixed/combined hyperlipidaemia with ezetimibe-containing medicines
2021     Ontario Health Skin substitutes for adults with diabetic foot ulcers and venous leg ulcers
2021     Ontario Health Repetitive Transcranial Magnetic Stimulation for People With Treatment-Resistant Depression
2021     Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU) Screening for common mental disorders during pregnancy and for traumatic experiences after delivery
2021     Ontario Health Pigmented lesion assay for suspected melanoma lesions
2021     Norwegian Institute of Public Health (NIPH) [Liposuction (lipectomy) for the treatment of fat accumulation caused by chronic lymphoedema]
2021     Ontario Health Proton Beam Therapy for Cancer in Children and Adults: A Health Technology Assessment
2021     Institut national d'excellence en sante et en services sociaux (INESSS) [Report: use of the SpaceOAR hydrogel rectal spacer during prostate radiotherapy]
2021     Center for Evidence-based Practice (CEP) COVID-19: mandatory vaccination
2021     Ontario Health Use of B-type natriuretic peptide and N Terminal-pro B-type natriuretic peptide as diagnostic tests in people with suspected heart failure
2021     Ontario Health Vaginal pessaries for pelvic organ prolapse and stress urinary incontinence
2021     Scottish Medicines Consortium (SMC) Secukinumab for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs)
2021     Scottish Medicines Consortium (SMC) Brentuximab vedotin in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL)
2021     Scottish Medicines Consortium (SMC) Melatonin (Slenyto) for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient
2020     Technology Assessment at SickKids (TASK) Microcosting of whole genome sequencing (WGS) of trios in heterogeneous pediatric cardiac population
2020     Center for Evidence-based Practice (CEP) COVID-19: prophylactic use of hydroxychloroquine (HCQ)